American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis
Launched by UNIVERSITY OF OXFORD · Feb 9, 2010
Trial Information
Current as of July 21, 2025
Unknown status
Keywords
ClinConnect Summary
The systemic vasculitides are a group of uncommon but important diseases whose prognosis has improved dramatically with the use of immunosuppressive therapy. However, long-term morbidity from recurrent disease flares, low-grade grumbling disease and/or accumulating damage from previous disease activity or drug therapy now characterise the long-term outlook for patients with vasculitis. There remains major controversy, and incompatibility between the ANCA-associated vasculitides: granulomatosis with polyangiitis (Wegener's), microscopic polyangiitis, and Churg Strauss Syndrome, as well as po...
Gender
ALL
Eligibility criteria
- Inclusion Criteria for Classification criteria:
- • 1. Adult patients aged \>18 years. There is no upper age limit.
- • 2. Ability to give informed consent. If the patient is unable to give informed consent as a result of death or physical incapacity, then informed assent from next of kin.
- • 3. Presumed diagnosis of a primary systemic vasculitis.
- Exclusion criteria for classification criteria:
- • 1. Patients \< 18 years of age.
- • 2. Inability to provide informed consent.
- • 3. Hepatitis B or C
- • 4. Co-morbidities that explain the clinical symptoms and signs on which the diagnosis of vasculitis is made. E.g. infection, tumour, other inflammatory condition, etc.
- Inclusion criteria for diagnostic criteria:
- • 1. Adult patients aged \>18 years. There is no upper age limit.
- • 2. Ability to give informed consent. If the patient is unable to give informed consent as a result of death or physical incapacity, then informed assent from next of kin.
- • 3. Suspected diagnosis of a primary systemic vasculitis
- Inclusion criteria for controls group for diagnostic criteria:
- • 1. Adult patients aged \>18 years. There is no upper age limit.
- • 2. Ability to give informed consent. If the patient is unable to give informed consent as a result of death or physical incapacity, then informed assent from next of kin.
- • 3. Patients presenting to secondary care with one of the following clinical presentations: I.Multi-system disease. Presentation of disease with at least 2 organs involved. II.Pulmonary-renal syndrome. Defined as haemoptysis / pulmonary haemorrhage with acute renal impairment. III.Acute renal failure IV.Acute respiratory distress. V.Chronic upper airways symptoms and signs. VI.Inflammatory polyarthritis. VII.Fever of unknown origin. VIII.Acute or chronic abdominal pain IX.Hypertension. X.Referred to secondary care with suspicion of vasculitis but confirmed not to have vasculitis. XII.New onset headache. XIII.Jaw or tongue pain. XIV.Sudden visual loss. XV.Limb claudication. XVI.Aortic aneurysm \>5cm.
- Exclusion Criteria for diagnostic criteria:
- • 1. Patients under the age of 18
- • 2. Patient or next of kin unable or unwilling to provide informed consent or assent.
About University Of Oxford
The University of Oxford, a prestigious institution renowned for its excellence in research and education, serves as a leading clinical trial sponsor dedicated to advancing medical science and improving patient care. With a rich history of innovation and a multidisciplinary approach, the university leverages its extensive expertise in various fields, including medicine, public health, and biomedical research, to conduct rigorous clinical trials. Collaborating with healthcare professionals, industry partners, and regulatory bodies, the University of Oxford aims to translate groundbreaking research findings into effective therapies and interventions, contributing to the global effort of enhancing health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Philadelphia, Pennsylvania, United States
Birmingham, Alabama, United States
San Francisco, California, United States
Baltimore, Maryland, United States
Pittsburgh, Pennsylvania, United States
Aberdeen, Scotland, United Kingdom
Uppsala, , Sweden
Cork, , Ireland
Pittsburgh, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Birmingham, Alabama, United States
Chapel Hill, North Carolina, United States
Cleveland, Ohio, United States
Herston, Queensland, Australia
Uppsala, , Sweden
Parma, , Italy
Norwich, , United Kingdom
Innsbruck, , Austria
Philadelphia, Pennsylvania, United States
Auckland, , New Zealand
Basel, , Switzerland
Helsinki, , Finland
Oxford, , United Kingdom
Okayama, , Japan
Amsterdam, , Netherlands
Leuven, , Belgium
Copenhagen, , Denmark
Osaka, , Japan
Münster, , Germany
Ankara, , Turkey
Romford, Essex, United Kingdom
Seoul, , Korea, Republic Of
Cambridge, , United Kingdom
Kanazawa, Ishikawa, Japan
Norwich, Norfolk, United Kingdom
Kagawa, , Japan
Chiba, , Japan
Winnipeg, Manitoba, Canada
Ipswich, Suffolk, United Kingdom
Hamilton, , New Zealand
Calgary, , Canada
Southampton, , United Kingdom
Reggio Emilia, , Italy
Jena, , Germany
Kristiansand, , Norway
Prague, , Czech Republic
Groningen, , Netherlands
Calgary, Alberta, Canada
Cleveland, Ohio, United States
Helsinki, , Finland
Chapel Hill, North Carolina, United States
Los Angeles, California, United States
San Francisco, California, United States
Boston, Massachusetts, United States
Ann Arbor, Michigan, United States
Lebanon, New Hampshire, United States
New York, New York, United States
Salt Lake City, Utah, United States
San Fernando Del Valle De Catamarca, Catamarca, Argentina
Buenos Aires, , Argentina
Canberra, Australian Capital Territory, Australia
Hamilton, Ontario, Canada
Ottawa, Ontario, Canada
Toronto, Ontario, Canada
Montreal, Quebec, Canada
Sherbrooke, Quebec, Canada
Ontario, , Canada
Beijing, , China
Prague, , Czech Republic
Assiut, , Egypt
Cairo, , Egypt
Paris, , France
Luebeck, , Germany
Plochingen, , Germany
Tübingen, , Germany
Debrecen, , Hungary
Lucknow, Uttar Pradesh, India
Chandigarh, , India
Hyderabad, , India
New Delhi, , India
Vellore, , India
Dublin 4, , Ireland
Reggio Emilia, , Italy
Kamogawa City, Chiba Prefecture, Japan
Tsukuba, Ibaraki Prefecture, Japan
Miyazaki City, Miyazaki Prefecture, Japan
Kawagoe, Saitama Prefecture, Japan
Mitaka, Tokyo Prefecture, Japan
Kanagawa, , Japan
Kanazawa, , Japan
Saitama, , Japan
Tochigi Ken, , Japan
Tokyo, , Japan
Mexico City, , Mexico
Mexico City, , Mexico
Amsterdam, , Netherlands
Groningen, , Netherlands
Christchurch, Canterbury, New Zealand
Auckland, , New Zealand
Tromsø, , Norway
Kraków, , Poland
Almada, , Portugal
Lisbon, , Portugal
Porto, , Portugal
Moscow, , Russian Federation
Ljubljana, , Slovenia
Barcelona, Catalonia, Spain
Columbo 8, , Sri Lanka
Lund, , Sweden
Stockholm, , Sweden
Stockholm, , Sweden
Umeå, , Sweden
Zurich, , Switzerland
Istanbul, , Turkey
Istanbul, , Turkey
Istanbul, , Turkey
Istanbul, , Turkey
Istanbul, , Turkey
Carlisle, Cumbria, United Kingdom
Basildon, Essex, United Kingdom
Westcliff On Sea, Essex, United Kingdom
Kirkcaldy, Fife, United Kingdom
Glasgow, Scotland, United Kingdom
Carshalton, Surrey, United Kingdom
Birmingham, , United Kingdom
Dudley, , United Kingdom
London, , United Kingdom
Manchester, , United Kingdom
Nottingham, , United Kingdom
Oxford, , United Kingdom
Reading, , United Kingdom
Slough, , United Kingdom
York, , United Kingdom
Patients applied
Trial Officials
Raashid A Luqmani, DM, FRCP(E)
Principal Investigator
University of Oxford, United Kingdom
Peter Merkel, MD, MPH
Principal Investigator
University of Pennsylvania
Richard Watts, DM, FRCP
Principal Investigator
University of East Anglia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials